16 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp08151 | ZXR-2 | FKIGGFIKKLWRSLLA | Synthetic | Ile/Leu residues crucially mediate cytolysis | LDH leakage assay | HeLa | Cervical Cancer | 40% LDH release at 32 μM |
| dbacp08152 | IL-1 | FKAGGFIKKLWRSLLA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | HeLa | Cervical Cancer | IC50 = 73.9 ± 13.6 μM |
| dbacp08153 | IL-1 | FKAGGFIKKLWRSLLA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | PC-3 | Prostate Cancer | IC50 = 58.4 ± 13.7 μM |
| dbacp08154 | IL-1 | FKAGGFIKKLWRSLLA | Synthetic | Ile/Leu residues crucially mediate cytolysis | LDH leakage assay | HeLa | Cervical Cancer | 30% LDH release at 32 μM |
| dbacp08155 | IL-2 | FKIGGFAKKLWRSLLA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | HeLa | Cervical Cancer | IC50 = 52.0 ± 5.8 μM |
| dbacp08156 | IL-2 | FKIGGFAKKLWRSLLA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | PC-3 | Prostate Cancer | IC50 = 43.6 ± 7.9 μM |
| dbacp08157 | IL-2 | FKIGGFAKKLWRSLLA | Synthetic | Ile/Leu residues crucially mediate cytolysis | LDH leakage assay | HeLa | Cervical Cancer | 30% LDH release at 32 μM |
| dbacp08158 | IL-3 | FKIGGFIKKAWRSLLA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | HeLa | Cervical Cancer | IC50 = 93.5 ± 19.4 μM |
| dbacp08159 | IL-3 | FKIGGFIKKAWRSLLA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | PC-3 | Prostate Cancer | IC50 = 74.9 ± 13.3 μM |
| dbacp08160 | IL-3 | FKIGGFIKKAWRSLLA | Synthetic | Ile/Leu residues crucially mediate cytolysis | LDH leakage assay | HeLa | Cervical Cancer | 35% LDH release at 32 μM |
| dbacp08161 | IL-4 | FKIGGFIKKLWRSALA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | HeLa | Cervical Cancer | IC50 = 54.4 ± 3.0 μM |
| dbacp08162 | IL-4 | FKIGGFIKKLWRSALA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | PC-3 | Prostate Cancer | IC50 = 35.5 ± 3.9 μM |
| dbacp08163 | IL-4 | FKIGGFIKKLWRSALA | Synthetic | Ile/Leu residues crucially mediate cytolysis | LDH leakage assay | HeLa | Cervical Cancer | 28% LDH release at 32 μM |
| dbacp08164 | IL-5 | FKIGGFIKKLWRSLAA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | HeLa | Cervical Cancer | IC50 = 28.0 ± 4.6 μM |
| dbacp08165 | IL-5 | FKIGGFIKKLWRSLAA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | PC-3 | Prostate Cancer | IC50 = 22.0 ± 2.6 μM |
| dbacp08166 | IL-5 | FKIGGFIKKLWRSLAA | Synthetic | Ile/Leu residues crucially mediate cytolysis | LDH leakage assay | HeLa | Cervical Cancer | 35% LDH release at 32 μM |